Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
Han X, Guo J, Li L, Huang Y, Meng X, Wang L, Zhu H, Meng X, Shao Q, Li X, Zhang Y, Wang J, Chen Y, Zhang Y, Chen Y, Zhu C, Wang Z.
Han X, et al. Among authors: chen y.
Signal Transduct Target Ther. 2024 Sep 16;9(1):241. doi: 10.1038/s41392-024-01957-3.
Signal Transduct Target Ther. 2024.
PMID: 39278918
Free PMC article.
Clinical Trial.